Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
NUV-422-02 is a first-in-human, open-label, Phase 1/2 dose escalation and multiple expansion
cohort study designed to evaluate the safety and efficacy of NUV-422. The study population is
comprised of adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast
cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic
castration-resistant prostate cancer (mCRPC). All patients will self-administer NUV-422
orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or
termination of the study.